Navigation Links
Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
Date:5/5/2011

SEATTLE, May 5, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its phosphodiesterase 7 (PDE7) inhibitors demonstrated robust efficacy in animal models of nicotine addiction.  These data add to earlier studies showing strong effects in models of cocaine addiction as well as binge eating.  Omeros' PDE7 program was founded on the Company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease.  Omeros believes that it also is the first to link PDE7 to any addiction or compulsive behavior, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse (NIDA) and The Michael J. Fox Foundation.

The studies, conducted by well-recognized addiction researcher R. Ciccocioppo, Ph.D., and his colleagues at the University of Camarino, demonstrated that PDE7 inhibitors reduced nicotine self-administration and inhibited relapse induced by cues and stress.  Smoking is the leading cause of preventable disease, disability and death in the United States, and it is estimated that 1.3 billion people worldwide, or approximately 20% of the world's population, are smokers. The smoking cessation market was estimated at $3.1 billion in 2007. Chantix® (varenicline) is the pharmaceutical market leader for the treatment of nicotine addiction.  However, Chantix® received a black box warning from the U.S. Food and Drug Administration highlighting the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking the drug.  PDE7 inhibitors are thought to exert their effect through a different mechanism than Chantix® and, therefore, may not have these side effects.

PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both movement and addiction. Omeros believes that PDE7 inhibitors could be effective therapeutics for the treatment of movement disorders as well as addiction and compulsive disorders. Omeros had previously shown in animal models of cocaine addiction that PDE7 inhibitors reduce cocaine self-administration, inhibit relapse induced by cues and stress, and facilitate drug abstinence in previously addicted animals. Importantly, no effect on normal feeding was observed in the cocaine studies, suggesting that PDE7 inhibitors selectively reduce addiction-related behaviors. In a similarly well-established animal model of binge eating, Omeros' PDE7 inhibitors demonstrated equally robust efficacy, again showing no effect on normal feeding behavior.

Omeros' PDE7 Program Expands its Addiction Franchise

As previously announced, Omeros is evaluating peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment of addiction in two Phase 2 clinical studies. NIDA is funding substantially all costs of these studies, which are evaluating the effects of PPARγ agonists on oxycontin and heroin use. Pilot human and preclinical data suggest that PPARγ agonists may be most effective in the treatment of addiction to opioids, alcohol and nicotine, and that they are less effective for treating addiction to psychostimulants such as cocaine and methamphetamine. In contrast, preclinical data suggest that phosphodiesterase 7 (PDE7) inhibitors may be effective in the treatment of addiction to cocaine and methamphetamine, nicotine and compulsive behaviors. Together, the PPARγ and PDE7 programs provide Omeros with a potentially broad franchise of drug treatments for addiction and compulsive disorders. In addition, Omeros also believes that it controls the worldwide rights to any PDE7 inhibitor for the treatment of any movement disorder, including Parkinson's disease, restless leg syndrome and Huntington's disease. Omeros has licensed its PDE7 inhibitors from Daiichi Sankyo Co., Ltd. for worldwide exclusivity in the fields of movement disorders, addictions and compulsive disorders.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include Omeros' belief that PDE7 inhibitors could be effective therapeutics for the treatment of movement disorders as well as addiction and compulsive disorders, that PDE7 inhibitors may not have the same side effects as Chantix®, that the PPARγ and PDE7 programs provide Omeros with a potentially broad franchise of drug treatments for addiction and compulsive disorders, and that Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/19/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will ... at the Sheraton Hotel in Toronto, Ontario . ... Company is scheduled to present on Tuesday, May 2 at 10:00 ... of the Board, Tony Holler will also attend the ... For more details about ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just ... unreal icons inhabiting the rarified air of pop and film stardom.(1) Not to be ... snapping pictures: the smile. Grins now run the gamut from being encrusted with jewels ...
(Date:4/24/2017)... ... ... Sean Fay is the undisputed king of the infomercial. With clients as ... Foreman Grill (which sold more than 100 million units worldwide), he has created more ... due to changes in the broadcast media landscape, the once ever-present infomercial has gone ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, ... 24 hours a day, Quick Care provides patients with the option to request ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to 78,000 ... 25,000 of them will be malignant.(1) As research into precision medicine continues, both ... model in the diagnosis and treatment of brain tumors. Healthcare facilities that are ...
Breaking Medicine News(10 mins):